190
Participants
Start Date
March 20, 2018
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
Antiandrogen Therapy
To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Docetaxel
To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
Laboratory Biomarker Analysis
Correlative studies
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Radical Prostatectomy
Undergo cytoreductive radical prostatectomy
TERMINATED
Epworth Healthcare, East Melbourne
TERMINATED
Unniversity of Pennsylvania, Philadelphia
RECRUITING
University of Southern California, Los Angeles
RECRUITING
City of Hope, Duarte
TERMINATED
University of California, Irvine, Irvine
RECRUITING
Swedish Medical Services, Seattle
RECRUITING
Yale University, New Haven
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
RECRUITING
Chinese University of Hong Kong, Hong Kong
RECRUITING
Akita University, Akita
RECRUITING
Juntendo University, Tokyo
RECRUITING
National Cancer Center, Goyang-si
RECRUITING
Seoul National University Bundang Hospital, Gyeonggi-do
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
National Taiwan University Hospital, Taipei
WITHDRAWN
Kyoto University, Sako
RECRUITING
Kindai University, Ōsaka-sayama
National Cancer Institute (NCI)
NIH
Yale University
OTHER